EGFR and gastric cancer: Targeted therapy based on anti-EGFR monoclonal antibodies (mAb) e.g., nimotuzumab, plus irinotecan, a common medication for gastric cancer treatment, showed potential improvement in EGFR positive patients of advanced gastric cancer [187].